NEW YORK - Pfizer has begun mid-to-late stage trials of an oral COVID-19 drug designed to prevent infection in those who have been exposed to the coronavirus.The drugmaker said Monday it has launched Phase 2/3 of a global clinical trial that aims to enroll up to 2,660 healthy adults who live in the same household as an individual with a confirmed, symptomatic COVID-19 infection. "If successful, we believe this therapy could help stop the virus early – before it has had a chance to replicate extensively – potentially preventing symptomatic disease in those who have been exposed and inhibiting the onset of infection in others," Dr.
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.